Title : The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice.

Pub. Date : 2020 Jan

PMID : 31628204






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice. Nicotine cytochrome P450 family 2 subfamily A member 6 Homo sapiens
2 During tobacco and e-cigarette use, nicotine is mainly metabolized in the human liver by CYP2A6. Nicotine cytochrome P450 family 2 subfamily A member 6 Homo sapiens
3 Given that a slower CYP2A6 metabolism has been associated with less vulnerability to develop nicotine dependence, the current studies sought to validate a novel CYP2A6 inhibitor, (5-(4-ethylpyridin-3-yl)thiophen-2-yl)methanamine (DLCI-1), for its effects on intravenous nicotine self-administration. Nicotine cytochrome P450 family 2 subfamily A member 6 Homo sapiens
4 Given that a slower CYP2A6 metabolism has been associated with less vulnerability to develop nicotine dependence, the current studies sought to validate a novel CYP2A6 inhibitor, (5-(4-ethylpyridin-3-yl)thiophen-2-yl)methanamine (DLCI-1), for its effects on intravenous nicotine self-administration. Nicotine cytochrome P450 family 2 subfamily A member 6 Homo sapiens